Synthesis of betulinic acid via Baylis-Hillman reaction by Kommineni, Sai Krishna
Rowan University 
Rowan Digital Works 
Theses and Dissertations 
8-22-2019 
Synthesis of betulinic acid via Baylis-Hillman reaction 
Sai Krishna Kommineni 
Rowan University 
Follow this and additional works at: https://rdw.rowan.edu/etd 
 Part of the Medicinal and Pharmaceutical Chemistry Commons 
Let us know how access to this document benefits you - 
share your thoughts on our feedback form. 
Recommended Citation 
Kommineni, Sai Krishna, "Synthesis of betulinic acid via Baylis-Hillman reaction" (2019). Theses and 
Dissertations. 2731. 
https://rdw.rowan.edu/etd/2731 
This Thesis is brought to you for free and open access by Rowan Digital Works. It has been accepted for inclusion 
in Theses and Dissertations by an authorized administrator of Rowan Digital Works. For more information, please 
contact LibraryTheses@rowan.edu. 















Submitted to the 
Department of Chemistry & Biochemistry 
College of Science & Mathematics 
In partial fulfillment of the requirement 
For the degree of 
Master of Science in Pharmaceutical Sciences 
at 
Rowan University 
June 29, 2019 
 
 
Thesis Chair: Subash C. Jonnalagadda, Ph.D. 
 
  































I dedicate this thesis to my dad Vallabha Rao and my mom Mani Mala for their unwavering 





Firstly, I would like to acknowledge my advisor Dr. Subash C. Jonnalagadda for 
his immense support, guidance and continued insights that guided me throughout this thesis 
work. He gave me the opportunity to explore and learn new skills. I would also like to 
express my sincere gratitude to Dr. Suman Pathi for his invaluable directions during my 
research work by helping me in learning new techniques and prompting me to focus on the 
quality of work. I will take this opportunity to acknowledge the lab members of 
Jonnalagadda research group for their help in completing this thesis and department of 






Sai Krishna Kommineni 
SYNTHESIS OF BETULINIC ACID DERIVATIVES VIA BAYLIS-HILLMAN 
REACTION 
2018-2019 
Subash Jonnalagadda, Ph.D. 
Master of Science in Pharmaceutical Sciences 
 
Betulin is readily isolated from the bark of birch trees using simple extraction 
techniques and this molecule as well as its derivatives (eg. betulinic acid) exhibit 
impressive levels of biological activity.  While it is naturally available and shows selective 
toxicity towards certain cancers, betulin suffers from a general lack of solubility in aqueous 
conditions.  In this regard, we took up a project involving the synthesis of conjugates of 
betulin with improved solubility characteristics and we were able to identify a series of 
compounds that showed cytotoxicity against breast and pancreatic cancer cells.  
This thesis describes our efforts on the development of betulinic acid-derived 
second generation candidate compounds as potential anti-cancer agents. In our previous 
attempts, we coupled the betulinic acid template with Baylis-Hillman reaction based 
cinnamamides using click reaction-derived triazoles as the linker.  We wanted to further 
explore the structure activity relationship profile for these conjugates. Accordingly, we 
synthesized two series of compounds (a) by removing the triazole linker and (b) by 
replacing the triazole with piperazine linker.  The biological evaluation of these series of 
compounds is underway and the data obtained from this study would pave way for further 
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 Betulin 1, betulinic acid 2 and their derivatives exhibit impressive levels of 
biological activity.1-4  Betulin is readily isolated from the bark of birch trees (10-15% w/w 
isolated yield) using simple extraction techniques.5-6    While betulin is readily available in 
nature, the corresponding carboxylic acid derivative betulinic acid 2, is known to exhibit 
more potent pharmacological activity.  There have been several reports and reviews on the 
potential applications of betulinic acid as anti-cancer, anti-HIV, anti-micotic, anti-









 Multi-component coupling reactions19,20 such as Passerini reaction,21-25 Ugi 
reaction,26 Baylis-Hillman reaction,27-34 click reaction, 35-38 etc. provide facile access  to 




medicinal and pharmaceutical chemistry toward drug design and development.  For the 
past several years, we have been working on the development of novel small molecules 
using reactions such as Baylis-Hillman reaction, Passerini reaction, click reaction, aldol 
condensation, reductive amination, etc. for potential applications in drug discovery.39-51 
We have also been working on the isolation and chemical functionalization of betulin using 
some of these methodologies11,18  particularly involving Baylis-Hillman and click reaction 
protocols.40 
Synthesis of Betulin Conjugates via Click Reaction 
 Click reaction involves the coupling of alkynes 4 with azides 3 in the presence of 
copper catalyst to yield substituted triazoles 5 (Figure 2).52-53 This cycloaddition reaction 
has been very thoroughly investigated and has found immense utility and applications in 












 Accordingly, several researchers have used click chemistry as a unique tool for the 
formation of several betulin and betulinic acid based triazole derivatives (Figures 3-10).  
Lee and coworkers described the reaction of betulin analog 7 and betulinic acid analog 10 
















  Khan et. al described the preparation of betulinic acid-triazole conjugates 13  via 
click reaction of propargyl ester of betulinic acid with aryl boronic acids in the presence of 








 Similarly, Thi and coworkers described the preparation of 16 via click coupling 












 Csuk and coworkers described the reaction of betulin aldehyde 17 with lithium 
acetylide followed by Jones Oxidation to produce the diketone 18 which upon reaction 














 Shi et. al described the synthesis of C30-triazole conjugates 22 starting from the 















 Chakraborty and coworkers described the synthesis of C3-triazole esters 25 via 
coupling of betulinic acid with chloroacetyl chloride followed by nucleophilic substitution 
with sodium azide to furnish 24, which was then subjected to click reaction with various 








































 Betulinic acid C3-triazole conjugates 27 were also synthesized and evaluated for 











Preparation of BH Reaction Derived Betulinic Acid Conjugates 
 Despite several reports on the synthesis of betulinic acid triazole derivatives using 
click reaction, limited success has been achieved in terms of identifying a potent lead 
compound for further development as a therapeutic agent.  Owing to the importance of 
Baylis-Hillman and click reactions, we undertook a project involving the preparation of 
betulinic acid triazole conjugates using these two reactions as the key steps in our 
synthesis.40  We initiated our synthesis with the acetylation of allylic alcohol 28 (obtained 
from Baylis-Hillman reaction of benzaldehyde with methyl acrylate) followed by treatment 
with N,N,N’-trimethylethylenediamine to furnish aminomethyl cinnamate 29.  Alkaline 
hydrolysis of 29 followed by the coupling of the resulting cinnamic acid with 2-
azidoethylamine in the presence of 1-hydroxybenzotriazole (HOBt), and 1-ethyl-3-(-3-
dimethylamino propyl) carbodimide hydrochloride (EDCI) furnished the 
azidoethylcinnamamide analog 30.  N-Propargyl betulinamide 31 was prepared in parallel 
by coupling betulinic acid with propargyl and was used for click reaction with azide 30.  
The resulting betulinic acid triazole amine conjugate 32 was purified and rigorously 
characterized via proton and carbon NMR and mass spectral analysis. Using a similar 
protocol outlined in Figure 11, a series of compounds 32a-e (Figure 12) were prepared 
and evaluated for biological efficacy as anti-cancer agents.  These studies formed the basis 




























































 Having identified a potent lead derivative 33 based on our initial studies, we set 
forth on a rational investigation of the role of individual components in imparting 
biological activity for these conjugates.  Accordingly, we took up a project involving the 
synthesis of betulinic acid conjugates of Baylis-Hillman template derived cinnamamides  
by either removing the triazole linker (34) or by replacing the triazole linker with piperazine 










Synthesis of N-2-Aminoethyl Cinnamamides 36-39 
To understand the structural activity relationship of the previously identified lead 
molecules we designed a study to know the importance of triazole as a linker and Baylis-
Hillman moiety in cytotoxic activity. Our primary choice for replacing triazole linker was 
piperazine/polyamines because of their well-established binding and solubility 
characteristics under pharmacological conditions. The two polyamines we utilized in our 
synthesis are 1,2-ethylenediamine and N,N’-bis(2-aminoethyl) piperazine. The 
ethylenediamine intermediates 36-39 (Figure 14) were hypothesized for final coupling 














Preparation of amine 36. The common intermediate required for the preparation 
of all four amines 36-39 was tbutoxycarbonyl (BOC) protected ethylenediamine 42.  The 
synthesis of 42 was achieved by adding a solution of Boc anhydride 41 in chloroform 
dropwise to a solution of ethylenediamine 40 in chloroform over a period of 30 minutes 
and maintaining the temperature 00C during the entire addition.  The resulting amine 42 









The reaction of cinnamic acid 43 with N-Boc-ethylenediamine 42 in the presence 
of hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDCI) and N, N-diisopropylethylamine (DIPEA) in methylene chloride (CH2Cl2) for 14 
hours resulted in the formation of N-Boc protected aminoethyl cinnamamide 44. 
Deprotection of Boc grop was carried out in acidic environment using trifluoroacetic acid 









Preparation of amine 37. The α-substituted cinnamic acid 51 required for the 
preparation of amine 37 was synthesized by following the previously reported protocol 
using Baylis-Hillman reaction as a key step. We began the synthesis by reacting 
benzaldehyde 45 with methyl acrylate 46 in the presence of DABCO at room temperature 
to yield the corresponding allylic alcohol 28. Acetylation of 28 was avhieved with acetic 
anhydride to furnish the acetate 49.  Reduction of 49 with sodium borohydride in methanol 
resulted in α-methylcinnamic acid methyl ester 50, which was subsequently hydrolyzed 
into acid 51 using aqueous sodium hydroxide in methanol and tetrahydrofuran (1:9).  This 
acid 51 was reacted with N-Boc ethylenediamine 42 in the presence of 
hydroxybenzotriazole (HOBt), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) 
and N,N-diisopropylethylamine (DIPEA) in methylene chloride (CH2Cl2) for 13 hours 




environment using trifluoroacetic acid in methylene chloride to yield the  corresponding 












Preparation of amine 38. The Baylis-Hillman reaction derived alcohol 28  was 
also used for the synthesis of amine 38.  The reaction of alcohol 28 with 
dimethylformamide dimethyl acetal in DMF under reflux conditions yielded the 
dimethylaminomethyl cinnamate 53.  Conversion of ester 53 to acid 54 was accomplished 
via alkaline hydrolysis using NaOH. The final coupling of acid 54 with N-Boc protected 
ethylenediamine 42 was achieved under peptide coupling conditions using HOBt and EDCI 











Preparation of amine 39. The allylic acetate 49 was treated with N-methyl 
piperazine and potassium carbonate in DMF to yield N-methylpiperazinylmethylcinnamate 
ester 57 via SN2’ substitution. Alkaline hydrolysis of ester 57 was realized upon reaction 
with 10% NaOH solution in THF:MeOH medium resulting in the formation of the acid 58. 
The final target amine 39 was obtained in two steps from 58 by coupling with N-Boc 
ethylenediamine 42 in the presence of hydroxybenzotriazole (HOBt),1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDCI) and N,N-diisopropylethylamine (DIPEA) in 
methylene chloride (CH2Cl2) followed by deprotection of 59 with trifloroacetic acid 












Preparation of Betulinic Acid Cinnamamide Conjugates 61a-d 
The final target compounds 61a-d were prepared in two steps starting from 
betulonic acid 60 involving sodium borohydride reduction followed by coupling with the 
four target amines 36-39 using O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium 
























Synthesis of Piperazinyl Cinnamamides 
To further establish the structural activity relationship profile of the previously 
synthesized triazole based lead molecules we explored the possibility of replacing the 
triazole linker with piperazine. The piperazinyl cinnamamide intermediates 62a-d (Figure 
22) were hypothesized for final coupling with betulinic acid towards the goal of preparing 











Preparation of N-boc-piperazinyl amine 66. N-boc-piperazinyl amine 66 was a 
common intermediate required for the synthesis of all four cinnamamides 62a-d. Thus, the 
synthesis of 66 was envisioned starting from piperazine 63 in three steps.  Piperazine was 
initially reacted with chloroacetonitrile in the presence of anhydrous sodium carbonate in 
ethanol under reflux conditions giving 1,4-piperazinediacetonitrile 64, which was 
dissolved in anhydrous tetrahydrofuran and added dropwise to a slurry of lithium 
aluminum hydride in anhydrous THF under nitrogen atmosphere while maintaining the 
temperature between 0-5 oC throughout the period of addition. The reaction mixture was 
then refluxed under nitrogen atmosphere for 4 hours. Finally, the quenching of excess 
lithium aluminum hydride was achieved via slow addition of 3 mL saturated sodium 
bicarbonate solution. The solution was filtered and concentrated to give a 1,4-bis(2-
aminoethyl) piperazine 65, which was monoprotected to yield the targe intermediate 66 by 













Preparation of piperazinyl cinnamamides 62a-d. The piperazinyl cinnamamide 
intermediates 62a-d were prepared starting from amine 66 by coupling with the four 
cinnamic acids 43 (Figure 16), 51 (Figure 17), 54 (Figure 18), and 58 (Figure 19). The 
coupling was achieved under hydroxybenzotriazole (HOBt), and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDCI)  conditions to yield 67a-d.  Deprotection of 
Boc group was achieved upon reaction with trifluoroacetic acid in methylene chloride to 





































R = H, 43
R = CH3, 51
R = CH2NMe2, 54













Preparation of Betulinic Acid-Piperazine Conjugates 69a-d 
The final target compounds 69a-d were prepared starting from betulinic acid 2 
coupling with the four target amines 62a-d using O-(benzotriazol-1-yl)-N,N,N',N'-























 We have been working on the development of betulin based small molecules as 
potential anti-cancer agents.  In this regard, we have identified few lead molecules 
(synthesized using Baylis-Hillman and click reactions as key steps) that exhibit potent 
cytotoxicity against breast cancer cells. The ample availability of betulin and betulinic acid 
from natural sources coupled with diverse functionalization opportunities possible with 
Baylis-Hillman reaction makes this project highly attractive for organic and medicinal 
chemistry community.  The lead derivatives consisted of a betulinic acid moiety and a 
Baylis-Hillman reaction-derived cinnamamide template that were coupled via triazole 
using click cycloaddition reaction.  In the second phase of this project, we decided to study 
the role of triazole linker in imparting biological activity. Accordingly, we designed two 
series of betulinic acid cinnamamide conjugates.  In the first series of conjugates, betulinic 
acid was coupled with cinnamamide without a triazole linker and in the second series the 
two entities were connected via piperazine linker instead of triazole.  The biological 
evaluation of these conjugates is underway and the results obtained from this study will 







Materials and Methods 
All the reactions were carried out under a N2 atmosphere in oven-dried glassware. 
Flash column chromatography (FCC) was carried out with SiliaFlash F60, 230-400 mesh 
silica gel. Reactions and column chromatography were monitored with SiliaPlate F254 
plates and visualized with potassium permanganate, or iodine stains. All the chemical 
reagents and solvents were used without further purification from commercial sources. 
Unless otherwise noted, melting points were obtained from material that solidified after 
chromatography. 
Instrumentation 
Proton and carbon NMR spectra (1H NMR and 13C NMR) were recorded in 
deuterated chloroform (CDCl3), unless otherwise noted on a Varian 400 MHz spectrometer 
with a quad-probe. Chemical shifts were reported in parts per million (ppm) and were 
calibrated according to residual protonated solvent. Low-resolution mass spectral analysis 
data was collected using an Agilent 1100-Series LC/MSD Trap LC-MS using acetonitrile 
with 0.1% formic acid in positive ionization mode. Purity of all final compounds were 
assessed on Agilent 1100 series HPLC equipped with a Sonoma 3µ (5cm x 2.1 mm) C18 















Preparation of tert-butyl (E)-(2-(2-methyl-3-phenylacrylamido)ethyl)carbamate 
52: N,N-Diisopropylethylamine (1.34 mL, 7.70 mmol), HOBt (457 mg, 3.39 mmol), and 
EDCI (647 mg, 3.39 mmol) were added at 0°C to a stirred solution of the acid 51 (500 mg, 
3.08 mmol) in dichloromethane (10.0 mL) and the reaction was stirred for 30 min. The 
appropriate amine (592 mg, 3.70 mmol) was added in one portion and the reaction was 
stirred overnight at room temperature. After completion of the reaction as indicated by 
TLC, the reaction mixture was quenched by the addition of saturated NaHCO3 solution and 
extracted with dichloromethane (2 x 10.0 mL). The combined extracts were washed with 
brine (10.0 mL), dried over anhydrous Na2SO4, concentrated in vacuo, and purified by 
column chromatography (silica gel, hexanes:ethyl acetate) to yield 610 mg (65%) of 52 as 
cream solid. Mp 120 – 123 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.37 (s, 1H), 7.20 – 
7.34 (m, 5H), 7.08 (br s, 1H), 5.36 (br s, 2H), 3.40 – 3.48 (m, 2H), 3.27 – 3.37 (m, 2H), 
2.06 (s, 3H), 1.40 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (ppm) 170.0, 157.4, 136.2, 









Preparation of tert-butyl (E)-(2-(2-((dimethylamino)methyl)-3-phenylacrylamido) 
ethylcarbamate 55: Procedure similar to that of 52. The reaction of acid 54 (200 mg, 0.97 
mmol), and tert-butyl (2-aminoethyl) carbamate 42 (187 mg, 1.17 mmol), yielded 227 mg  
(67%) of 55 as pale cream solid. Mp 112 – 114 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 
9.75 (br s, 1H), 7.86 (s, 1H), 7.32 – 7.37 (m, 2H), 7.23 – 7.30 (m, 1H), 7.19 – 7.24 (m, 2H), 
5.14 (br s, 1H), 3.40 – 3.47 (m, 2H), 3.34 (s, 2H), 3.25 – 3.32 (m, 2H), 2.19 (s, 6H), 1.41 
(s, 9H); 13C NMR (101 MHz, CDCl3): δ (ppm) 168.9, 156.2, 139.7, 135.6, 130.5, 















Preparation of tert-butyl(E)-(2-(2-((4-methylpiperazin-1-yl)methyl) -3-




acid 58 (150 mg, 0.58 mmol), and tert-butyl (2-aminoethyl) carbamate 42 (110 mg, 0.69 
mmol), yielded 153 mg (66%) of 59 as pale cream solid. Mp 135 – 137 °C; 1H NMR 
(400 MHz, CDCl3): δ (ppm) 9.72 (br s, 1H), 7.93 (s, 1H), 7.27 – 7.40 (m, 3H), 7.17 – 
7.27 (m, 2H), 4.98 (br s, 1H), 3.43 – 3.52 (m, 2H), 3.40 (s, 2H), 3.31 (q, J = 6.0 Hz, 2H), 
2.31 – 2.70 (m, 8H), 2.29 (s, 3H), 1.44 (s, 9H); 13C NMR (101 MHz, CDCl3): δ (ppm) 
168.7, 156.2, 140.2, 135.5, 129.7, 128.9, 128.2, 127.9, 79.1, 55.1, 54.7, 52.2, 45.8, 40.8, 
39.2, 28.4. 
Preparation of compounds 36-39: To a stirred solution of appropriate Boc-protected 
amines (1.0 mmol) in dichloromethane (10.0 mmol) at 0°C, was added trifluoro acetic acid 
(2.0 mL) slowly dropwise. The reaction mixture was stirred at room temperature overnight. 
The solvent was removed in vacuo, the resulting slurry was diluted with cold water and 
adjusted pH to basic with 10% NaOH solution. The amine was extracted with ethyl acetate 
(2 x 10.0 mL), the combined extracts were extracted washed with saturated NaCl solution 
and dried over anhydrous Na2SO4. The solution was concentrated in vacuo, the resulting 













Preparation of compound 61a: To a solution of betulinic acid 2 (250 mg, 0.55 
mmol) in DMF (5.0 mL), were added N,N-diisopropylethylamine (191 µL, 1.10 mmol), 
and TBTU (194 mg, 0.60 mmol) at 0 °C. The solution was stirred for 30 min whereupon 
the appropriate amine 36 (157 mg, 0.82 mmol) was added and the mixture was stirred 
overnight at room temperature. Upon completion (TLC), the reaction mixture was 
quenched by the addition of saturated NaHCO3 solution and extracted with ethyl acetate (2 
x 10.0 mL). The combined extracts were washed with cold water (10.0 mL) and brine (10.0 
mL). The organic layer was dried over anhydrous Na2SO4, concentrated in vacuo, and 
purified by column chromatography (silica gel, hexanes:ethyl acetate) to afford 257 mg 
(67%) of 61a as pale cream solid. Mp 112 – 114 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 
7.60 (d, J = 15.7 Hz, 1H), 7.47 – 7.53 (m, 2H), 7.32 – 7.38 (m, 3H), 6.62 (t, J = 4.7 Hz, 
1H), 6.39 (d, J = 15.7 Hz, 1H), 6.25 (t, J = 5.3 Hz, 1H), 4.73 (d, J = 1.8 Hz, 1H), 4.58 (s, 
1H), 3.49 – 3.63 (m, 3H), 3.34 – 3.41 (m, 1H), 3.06 – 3.17 (m, 2H),  
2.43 (td, J = 3.6, 12.4 Hz, 1H), 1.86 – 2.00 (m, 2H), 0.59 – 1.76 (m, 21H), 1.67 (s, 3H), 
0.93 (s, 3H), 0.91 (s, 3H), 0.87 (s, 3H), 0.68 (s, 6H); 13C NMR (101 MHz, CDCl3): δ (ppm) 




 50.1, 46.8, 42.4, 41.2, 40.7, 39.6, 38.8, 38.6, 38.4, 37.7, 37.1, 34.2, 33.6, 30.9, 29.5, 27.9, 
27.4, 25.6, 20.9, 19.4, 18.1, 16.2, 15.9, 15.3, 14.6; ESIMS: m/z calculated for C41H60N2O3 








Preparation of compound 61b: Procedure similar to that of 61a. The reaction of 
betulinic acid 2 (120 mg, 0.26 mmol), and appropriate amine 37 (80 mg, 0.39 mmol), 
yielded 120 mg (71%) of 61b as cream solid. Mp 125 – 127 °C; 1H NMR (400 MHz, 
CDCl3): δ (ppm) 7.27 – 7.42 (m, 6H), 7.09 (br s, 1H), 6.40 – 6.45 (m, 1H), 4.57 (s, 1H), 
4.69 (s, 1H), 3.41 – 3.56 (m, 4H), 3.08 – 3.20 (m, 2H), 2.35 (dt, J = 3.6, 12.3 Hz, 1H), 2.11 
(d, J = 1.4 Hz, 3H), 1.86 – 2.02 (m, 1H), 0.61 – 1.77 (m, 23H), 1.65 (s, 3H), 0.94 (s, 3H), 
0.93 (s, 3H), 0.85 (s, 3H), 0.72 (s, 6H); 13C NMR (101 MHz, CDCl3): δ (ppm) 178.4, 170.2, 
150.8, 136.1, 134.4, 131.3, 129.4, 128.3, 127.8, 109.4, 78.9, 55.7, 55.3, 50.5, 50.1, 46.9, 
42.4, 41.8, 40.6, 39.6, 38.8, 38.6, 38.4, 37.9, 37.1, 34.3, 33.6, 30.9, 29.5, 27.9, 27.4, 25.5, 













Preparation of compound 61c: Procedure similar to that of 61a. The reaction of acid 
2 (100 mg, 0.22 mmol), and appropriate amine 38 (82 mg, 0.33 mmol), yielded 104 mg 
(69%) of 61c as cream solid. Mp 115 – 117 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.99 
(t, J = 5.9 Hz, 1H), 7.90 (s, 1H), 7.28 – 7.39 (m, 3H), 7.20 – 7.24 (m, 2H), 6.67 (t, J = 4.6 
Hz, 1H), 4.73 (d, J = 2.4 Hz, 1H), 4.58 (d, J = 2.4 Hz, 1H), 3.35 – 3.58 (m, 4H), 3.32 (s, 
2H), 3.12 – 3.20 (m, 2H), 2.41 (dt, J = 3.5, 12.8 Hz, 1H), 2.18 (s, 6H), 0.64 – 2.06 (m, 
23H), 1.67 (s, 3H), 0.95 (s, 3H), 0.94 (s, 3H), 0.91 (s, 3H), 0.79 (s, 3H), 0.74 (s, 3H); 13C 
NMR (101 MHz, CDCl3): δ (ppm) 176.8, 169.7, 151.1, 140.0, 135.6, 130.4, 129.0, 128.2, 
127.9, 109.2, 78.9, 56.2, 55.6, 55.3, 50.6, 50.2, 46.8, 44.5, 42.4, 41.3, 40.7, 38.8, 38.7, 38.5, 
38.3, 37.8, 37.2, 34.4, 33.5, 30.9, 29.5, 27.9, 27.4, 25.6, 20.9, 19.5, 18.2, 16.2, 16.1, 15.4, 
14.6; ESIMS: m/z calculated for C44H67N3O3 (M+H)









Preparation of compound 61d: Procedure similar to that of 61a. The reaction of 
acid 2 (125 mg, 0.27 mmol), and appropriate amine 39 (122 mg, 0.41 mmol), yielded  
132 mg (65%) of 61d as cream solid. Mp 121 – 123 °C; 1H NMR (400 MHz, CDCl3): δ 
(ppm) 9.82 (t, J = 5.9 Hz, 1H), 7.87 (s, 1H), 7.22 – 7.31 (m, 3H), 7.17 (d, J = 7.1 Hz, 3H), 
6.76 (t, J = 4.5 Hz, 1H), 4.67 (s, 1H), 4.52 (s, 1H), 3.05 – 3.28 (m, 4H), 3.36 (s, 2H), 2.16 
– 2.56 (m, 9H), 2.23 (s, 3H), 1.82 – 2.06 (m, 2H), 0.58 – 1.82 (m, 23H), 1.62 (s, 3H), 0.90 
(s, 3H), 0.89 (s, 3H), 0.85 (s, 3H), 0.73 (s, 3H), 0.68 (s, 3H); 13C NMR (101 MHz, CDCl3): 
δ (ppm) 176.8, 169.5, 151.0, 140.7, 135.3, 129.4, 128.9, 128.3, 128.0, 109.2, 78.6, 55.6, 
55.3, 55.1, 54.7, 52.1, 50.5, 50.1, 46.8, 45.8, 42.4, 41.5, 40.6, 38.8, 38.7, 38.5, 38.3, 37.7, 
37.1, 34.3, 33.4, 30.9, 29.5, 28.0, 27.4, 25.6, 20.9, 19.4, 18.2, 16.2, 16.1, 15.4, 14.6; 
ESIMS: m/z calculated for C47H72N4O3 (M+H)










Preparation of compound 67b: Procedure similar to that of 52. The reaction of acid 
51 (250 mg, 1.54 mmol), and amine 66 (630 mg, 2.31 mmol), yielded 392 mg (61%) of 
67b as white solid. Mp 107 – 109 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.26 – 7.40 
(m, 6H), 6.54 (br s, 1H), 4.96 (s, 1H), 3.38 – 3.46 (m, 2H), 3.16 – 3.26 (m, 2H), 2.57 (t, J 
= 6.1 Hz, 2H), 2.38 – 2.53 (m, 8H), 2.45 (t, J = 6.1 Hz, 2H), 2.08 (d, J = 1.6 Hz, 3H), 1.44 
(s, 9H); 13C NMR (101 MHz, CDCl3): δ (ppm) 169.3, 155.9, 136.2, 133.8, 131.9, 129.3, 








Preparation of compound 67c: Procedure similar to that of 52. The reaction of acid 





67c as orange semi solid. 1H NMR (400 MHz, CDCl3): δ (ppm) 9.83 (br s, 1H), 7.88 (s, 
1H), 7.30 – 7.35 (m, 2H), 7.24 – 7.28 (m, 1H), 7.19 – 7.23 (m, 2H), 5.02 (s, 1H), 3.40 – 
3.48 (m, 2H), 3.29 (s, 2H), 3.17 – 3.24 (m, 2H), 2.52 (t, J = 6.1 Hz, 2H), 2.44 (t, J = 6.0 
Hz, 2H), 2.38 – 2.57 (m, 8H), (2.16 (s, 6H), 1.42 (s, 9H); 13C NMR (101 MHz, CDCl3): δ 
(ppm) 168.1, 155.9, 139.2, 135.9, 130.9, 129.0, 128.2, 127.6, 57.2, 56.8, 56.1, 53.1, 52.9, 








Preparation of compound 69b: Procedure similar to that of 61a. The reaction of 
acid 2 (90 mg, 0.19 mmol), and amine 62b (94 mg, 0.29 mmol), yielded 106 mg (71%) of 
69b as cream solid. Mp 120 – 121 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.26 – 7.40 
(m, 6H), 6.52 (t, J = 4.4 Hz, 2H), 6.22 (t, J = 4.8 Hz, 1H), 4.73 (s, 1H), 4.59 (s, 1H), 3.42 
– 3.49 (m, 2H), 3.26 – 3.38 (m, 2H), 3.17 (dd, J = 5.0, 11.1 Hz, 1H), 3.07 (dt, J = 3.7, 11.0 
Hz, 1H), 2.56 (t, J = 6.0 Hz, 2H), 2.49 (t, J = 6.1 Hz, 2H), 2.40 – 2.61 (m, 8H), 2.35 (dt, J 




1.68 (s, 3H), 0.96 (s, 3H), 0.95 (s, 3H), 0.91 (s, 3H), 0.80 (s, 3H), 0.74 (s, 3H); 13C NMR 
(101 MHz, CDCl3): δ (ppm) 176.1, 169.4, 150.8, 136.2, 133.9, 131.9, 129.3, 128.3, 127.8, 
109.4, 78.9, 56.3, 56.2, 55.8, 55.4, 52.9, 52.8, 50.5, 49.9, 47.0, 42.5, 40.7, 38.8, 38.7, 38.4, 
37.9, 37.2, 36.3, 35.6, 34.4, 33.7, 30.9, 29.4, 27.9, 27.4, 25.6, 20.9, 19.4, 18.3, 16.2, 16.1, 
15.4, 14.7, 14.2; ESIMS: m/z calculated for C48H74N4O3 (M+H)
+ 755.59, found 755.79; 








Preparation of compound 69c: Procedure similar to that of 61a. The reaction of acid 
2 (125 mg, 0.27 mmol), and amine 62c (148 mg, 0.41 mmol), yielded 95 mg (68%) of 69c 
as cream solid. Mp 127 – 130 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.86 (br s, 1H), 
7.90 (s, 1H), 7.18 – 7.37 (m, 5H), 6.26 (br s, 1H), 4.73 (s, 1H), 4.58 (s, 1H), 3.40 – 3.51 
(m, 2H), 3.26 – 3.38 (m, 2H), 3.31 (s, 2H), 3.16 (dd, J = 5.0, 11.1 Hz, 1H), 3.07 (dt, J = 
3.8, 11.1 Hz, 1H), 2.41 – 2.56 (m, 12H), 2.30 – 2.39 (m, 1H), 2.18 (s, 6H), 1.88 – 2.05 (m, 




3H), 0.74 (s, 3H); 13C NMR (101 MHz, CDCl3): δ (ppm) 176.2, 168.1, 150.9, 139.3, 135.9, 
130.9, 129.0, 128.2, 127.7, 109.4, 78.9, 56.8, 56.4, 56.1, 55.9, 55.4, 53.0, 52.9, 50.5, 49.9,  
47.0, 44.6, 42.5, 40.7, 38.8, 38.7, 38.4, 37.9, 37.2, 36.6, 35.6, 34.4, 33.7, 30.9, 29.4, 27.9, 
27.4, 25.6, 20.9, 19.4, 18.3, 16.2, 16.1, 15.3, 14.7; ESIMS: m/z calculated for C50H79N5O3 








Preparation of compound 69a: Procedure similar to that of 61a. The reaction of acid 
2 (100 mg, 0.22 mmol), and amine 62a (99 mg, 0.33 mmol), yielded 94 mg (57%) of 69a 
as cream solid. Mp 110 – 113 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.62 (d, J = 15.6 
Hz, 1H), 7.48 – 7.53 (m, 2H), 7.31 – 7.41 (m, 3H), 6.41 (d, J = 15.6 Hz, 1H), 6.16 – 6.25 
(m, 2H), 4.59 (s, 1H), 4.73 (d, J = 2.3 Hz, 1H), 3.45 – 3.52 (m, 2H), 3.27 – 3.40 (m, 2H), 
3.17 (dd, J = 5.0, 11.1 Hz, 1H), 3.08 (dt, J = 3.8, 11.1 Hz, 1H), 2.42 – 2.59 (m, 12H), 2.36 
(dt, J = 3.6, 12.4  Hz, 1H), 1.90 – 2.06 (m, 2H), 0.62 – 1.80 (m, 22H), 1.68 (s, 3H), 0.96 




δ (ppm) 176.1, 165.8, 150.9, 140.9, 134.9, 129.6, 128.8, 127.8, 120.7, 109.4, 78.9, 56.5, 
56.3, 55.9, 55.4, 53.0, 52.7, 50.5, 49.8, 47.0, 42.5, 40.7, 38.8, 38.7, 38.4, 37.9, 37.2, 36.1,  
35.6, 34.4, 33.7, 30.9, 29.4, 27.9, 27.4, 25.6, 20.9, 19.4, 18.3, 16.2, 16.1, 15.4, 14.7; 
ESIMS: m/z calculated for C47H72N4O3 (M+H)









Preparation of compound 69d: Procedure similar to that of 61a. The reaction of 
acid 2 (80 mg, 0.18 mmol), and amine 62d (108 mg, 0.27 mmol), yielded 82 mg (54%) of 
69d as cream solid. Mp 131 – 133 °C; 1H NMR (400 MHz, CDCl3): δ (ppm) 9.56 (br s, 
1H), 7.93 (s, 1H), 7.32 – 7.37 (m, 2H), 7.22 – 7.31 (m, 3H), 6.24 (br s, 1H), 4.74 (d, J = 
2.4 Hz, 1H), 4.59 (s, 1H), 3.46 – 3.54 (m, 2H), 3.39 (s, 2H), 3.29 – 3.38 (m, 2H), 3.18 (dd, 
J = 4.9, 11.2 Hz, 1H), 3.08 (dt, J = 3.8, 11.1 Hz, 1H), 2.31 – 2.62 (m, 21H), 2.29 (s, 3H), 
1.89 – 2.07 (m, 2H), 0.63 – 1.81 (m, 22H), 1.69 (s, 3H), 0.97 (s, 3H), 0.96 (s, 3H), 0.92 (s, 





 140.1, 135.7, 129.9, 128.9, 128.2, 127.8, 109.4, 78.9, 57.3, 56.4, 55.9, 55.4, 55.1, 54.8, 
53.2, 52.8, 52.3, 50.5, 49.9, 47.0, 45.9, 42.5, 40.7, 38.8, 38.7, 38.4, 37.9, 37.2, 36.6, 35.6, 
 34.4, 33.7, 30.9, 29.7, 29.4, 27.9, 27.4, 25.6, 20.9, 19.4, 18.3, 16.2, 16.1, 15.3, 14.7; 
ESIMS: m/z calculated for C53H84N6O3 (M+H)







Chapter 4 - Spectral Characterization  
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